New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications
- 1 September 2002
- journal article
- review article
- Published by Elsevier in Clinics in Dermatology
- Vol. 20 (5) , 505-514
- https://doi.org/10.1016/s0738-081x(02)00271-7
Abstract
No abstract availableThis publication has 62 references indexed in Scilit:
- Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitisJournal of Allergy and Clinical Immunology, 2001
- Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2001
- Treatment of Pemphigus Vulgaris and Bullous Pemphigoid With Mycophenolate Mofetil MonotherapyArchives of Dermatology, 1999
- Recalcitrant pyoderma gangrenosum treated with systemic tacrolimusBritish Journal of Dermatology, 1999
- Dyshidrotic Eczema Treated With Mycophenolate MofetilArchives of Dermatology, 1998
- Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study GroupArchives of Dermatology, 1996
- TacrolimusDrugs, 1993
- Anti-Inflammatory Effect of FK-506 on Human Skin Mast CellsJournal of Investigative Dermatology, 1992
- Immunosuppressive Macrolides of the Type FK 506: A Novel Class of Topical Agents for Treatment of Skin Diseases?Journal of Investigative Dermatology, 1992
- MYCOPHENOLIC ACID AN ANTIBIOTIC FROM PENICILLIUM BREVICOMPACTUM DIERCKXThe Lancet, 1946